Identigene STD Test Collection Kit Validation Study
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 14 - Any |
| Updated: | 4/2/2016 |
| Start Date: | November 2011 |
| End Date: | June 2014 |
| Contact: | Michael Smith |
| Email: | mikes@lifetreeresearch.com |
| Phone: | 801-859-7818 |
The overall goal of the present study is to provide evidence of concordant test results
using the Identigene STD Test Collection Kit for self-collection and transport of specimens
to a qualified testing laboratory. It is expected that this method will aid in detection of
CT and NG and that offering a method of self-collection of a male urine or female vaginal
swab specimen will encourage testing for CT and NG and improve the overall detection of
reporting of these STDs by allowing persons who suspect they have the infection to be tested
in a discrete and confidential manner. The reporting of CT and NG are underestimated and
many subjects will not visit a clinic or obtain treatment if gone undetected. Thus, allowing
a self-collection kit that is more convenient may result in improved reporting,
identification of CT and NG positive individuals, and subsequent treatment to help prevent
the spread of these diseases.
The purpose of this study is to demonstrate that the Identigene STD Test Collection Kit and
labeled instructions for use instructions provide test results that are concordant (at least
95% or better) with test results obtained using the Gen-Probe APTIMA Combo 2 specimen
collection and transport methods performed under the supervision of a healthcare provider.
The laboratory technology and test method used for the IDTG-100.
using the Identigene STD Test Collection Kit for self-collection and transport of specimens
to a qualified testing laboratory. It is expected that this method will aid in detection of
CT and NG and that offering a method of self-collection of a male urine or female vaginal
swab specimen will encourage testing for CT and NG and improve the overall detection of
reporting of these STDs by allowing persons who suspect they have the infection to be tested
in a discrete and confidential manner. The reporting of CT and NG are underestimated and
many subjects will not visit a clinic or obtain treatment if gone undetected. Thus, allowing
a self-collection kit that is more convenient may result in improved reporting,
identification of CT and NG positive individuals, and subsequent treatment to help prevent
the spread of these diseases.
The purpose of this study is to demonstrate that the Identigene STD Test Collection Kit and
labeled instructions for use instructions provide test results that are concordant (at least
95% or better) with test results obtained using the Gen-Probe APTIMA Combo 2 specimen
collection and transport methods performed under the supervision of a healthcare provider.
The laboratory technology and test method used for the IDTG-100.
This is a multicenter study involving asymptomatic and symptomatic subjects who are at risk
or suspect possible exposure to CT and/or NG. Approximately five (5) clinics will
participate in the study. The clinics selected will be located in diverse geographical
regions in order to represent populations with both high and low incidences of CT and NG and
to represent different extremes in climate. The initial phase of the study enrolled
approximately 500 qualifying subjects. An interim analysis was performed to determine
whether changes in the study protocol were necessary. Changes to the protocol were
identified and are incorporated in this amendment (amendment 4) of the study protocol.
Specifically, males in the study will still collect urine specimens whereas women will now
self-collect a vaginal swab specimen. Study subjects will only undergo one clinic visit
rather than two as indicated in prior versions of the study protocol. The proposed study
phases outlined in this amendment of the study protocol will include at least 200 qualifying
subjects with intermittent suspension of the study to allow data analysis. The present study
will continue until 200 CT positive test results (approximately 100 male and 100 female) are
obtained. Of these 200 positive results, approximately 50% will be from symptomatic subjects
and 50% from asymptomatic subjects. Since the positivity rate is presumably lower for
asymptomatic subjects, the ration of symptomatic to asymptomatic subject enrollment for each
study phase will be determined by the sponsor and will be made known in writing to each
study site.
It is expected that approximately 3,000 subjects will be required to meet the overall study
objectives. It is anticipated that the total number of subjects enrolled for testing
throughout the study will yield approximately 30 positive NG samples (approximately 15 males
and 15 females) with no requirement for a specific ratio of symptomatic to asymptomatic
subjects. Subjects who are at high risk of exposure or suspect exposure to CT or NG, but are
not currently being treated, will be recruited for enrollment.
or suspect possible exposure to CT and/or NG. Approximately five (5) clinics will
participate in the study. The clinics selected will be located in diverse geographical
regions in order to represent populations with both high and low incidences of CT and NG and
to represent different extremes in climate. The initial phase of the study enrolled
approximately 500 qualifying subjects. An interim analysis was performed to determine
whether changes in the study protocol were necessary. Changes to the protocol were
identified and are incorporated in this amendment (amendment 4) of the study protocol.
Specifically, males in the study will still collect urine specimens whereas women will now
self-collect a vaginal swab specimen. Study subjects will only undergo one clinic visit
rather than two as indicated in prior versions of the study protocol. The proposed study
phases outlined in this amendment of the study protocol will include at least 200 qualifying
subjects with intermittent suspension of the study to allow data analysis. The present study
will continue until 200 CT positive test results (approximately 100 male and 100 female) are
obtained. Of these 200 positive results, approximately 50% will be from symptomatic subjects
and 50% from asymptomatic subjects. Since the positivity rate is presumably lower for
asymptomatic subjects, the ration of symptomatic to asymptomatic subject enrollment for each
study phase will be determined by the sponsor and will be made known in writing to each
study site.
It is expected that approximately 3,000 subjects will be required to meet the overall study
objectives. It is anticipated that the total number of subjects enrolled for testing
throughout the study will yield approximately 30 positive NG samples (approximately 15 males
and 15 females) with no requirement for a specific ratio of symptomatic to asymptomatic
subjects. Subjects who are at high risk of exposure or suspect exposure to CT or NG, but are
not currently being treated, will be recruited for enrollment.
Inclusion Criteria:
1. Symptomatic females or males, age 14 or older, who present at a participating clinic
with symptoms consistent with Chlamydia trachomatis or Neisseria gonorrhoeae
infection, or
2. Asymptomatic females or males, age 14 or older, who present at a participating clinic
and who suspect that they have CT and/or NG, or are considered at high risk of
exposure (e.g., sexual partner that tests positive for CT, or NG, multiple sexual
partners, ect.),
3. Individuals who are capable of understanding and agree to fulfill the requirements of
the protocol.
4. Individuals who have signed the IRB approved informed consent form.
Exclusion Criteria:
1. Individuals with physical or mental inability that, in the opinion of the
investigator can interfere with the subject's ability to follow the Identigene STD
Test Collection Kit instructions,
2. Individuals who are currently being treated for CT or NG or who are currently
receiving antibiotics or have received antibiotics within the last 28 days, and
3. Individuals who are suspected of being victims of sexual abuse or nonconsensual
contact of a sexual nature within the previous 6 months or who are part of an ongoing
sexual abuse legal case.
We found this trial at
1
site
Click here to add this to my saved trials
